FICCI announces online certificate course on IPR and pharmaceutical R&D

FICCI -CCIPR Course

Federation of Indian Chambers of Commerce and Industry (FICCI) has been running an Online Certificate Course on IPR and Pharmaceutical R&D (CCIPR). The objective of the Course is to provide the platform to understand the working of pharmaceutical industry, its business models, research, regulatory aspects and its relevance with respect to intellectual property rights.

Registration Start Date:              1st October 2013

Registration Closing Date:          25th October 2013

Conduct of the Course:              November 2013 – April 2014

Course Duration:                         6 Months

This is first of its kind of course introduced with specific focus on the interlinking between the pharmaceutical industry and IPR. The Course is of 6 months duration and consists of Five (5) modules i.e. pharmaceutical business, pharmaceutical research and development, intellectual property rights: introduction, IPR – With specific reference to pharmaceuticals, IPR – Indian patent scenario and a case paper to be prepared by the participant.

The Course may be pursued by any student in pharmacy/ pharmaceutical sciences or industry persons working in the pharmaceutical sector, willing to enter pharmaceutical R&D, formulations, generics, NDDS, regulatory affairs, drug discovery, clinical research, toxicology, international business, business strategy, strategic planning and the like.

Features like Online FORUM for query resolution and fortnightly updates on IPR to registrants make the course interactive.

For further details, the readers are requested to visit the website – – www.ficciipcourse.in or e-mail at [email protected] .

Tags:

1 thought on “FICCI announces online certificate course on IPR and pharmaceutical R&D”

  1. Sir,
    I am a BPharmacy graduate with 8 years of experience in pharma industry. I learned about your IPR courses. I am interested in the IPR course.

Leave a Comment

Discover more from SpicyIP

Subscribe now to keep reading and get access to the full archive.

Continue reading

Scroll to Top